Mounjaro vs. Wegovy vs. Ozempic, which one's right for you?
All three are GLP-1-based weight loss treatments, but they're not interchangeable. Mounjaro (tirzepatide) acts on two appetite-regulating receptors instead of one, and generally shows stronger average results. Wegovy and Ozempic share the same active ingredient (semaglutide) but are approved for different primary uses. The right choice depends on your health history, goals, and what your physician recommends after reviewing your labs, not on which name you've heard most.
All three are GLP-1-based weight loss treatments, but they're not interchangeable. Mounjaro (tirzepatide) acts on two appetite-regulating receptors instead of one, and generally shows stronger average results. Wegovy and Ozempic share the same active ingredient (semaglutide) but are approved for different primary uses. The right choice depends on your health history, goals, and what your physician recommends after reviewing your labs, not on which name you've heard most.
Mounjaro (Tirzepatide)
Mounjaro (Tirzepatide)
The dual-action option — why it works on two receptors, not one
The dual-action option — why it works on two receptors, not one
Tirzepatide targets both GLP-1 and GIP receptors, which is part of why it often outperforms single-receptor medications in head-to-head data.
Tirzepatide targets both GLP-1 and GIP receptors, which is part of why it often outperforms single-receptor medications in head-to-head data.
See the full Mounjaro page →
See the full Mounjaro page →
Wegovy / Ozempic (Semaglutide)
Wegovy / Ozempic (Semaglutide)
The established option — what years of real-world data show
The established option — what years of real-world data show
Semaglutide has one of the longest real-world safety and efficacy track records of any GLP-1 medication, with Wegovy approved specifically for weight management and Ozempic primarily for Type 2 diabetes.
Semaglutide has one of the longest real-world safety and efficacy track records of any GLP-1 medication, with Wegovy approved specifically for weight management and Ozempic primarily for Type 2 diabetes.
See the full Wegovy page →
See the full Wegovy page →
What actually matters more than the brand name
20–40%
20–40%
of total weight lost can come from muscle, regardless of which GLP-1 you choose
of total weight lost can come from muscle, regardless of which GLP-1 you choose
2/3
2/3
of lost weight typically returns within a year of stopping, without monitoring
of lost weight typically returns within a year of stopping, without monitoring
Here's what most comparisons miss: the medication is only part of the outcome. The bigger question isn't which drug is ‘best’, it's whether your program is actually tracking what you're losing, and supporting you after you stop.
How we help you choose
Free physician consultation
Talk to a physician before committing to anything. We'll review your health history and goals to recommend the option that actually fits you, at no cost for the initial consultation.
Lab-based eligibility assessment, not guesswork
Your recommendation is based on real lab results and a full clinical picture, not just which medication is trending.
| Mounjaro | Wegovy (Injection) | Wegovy Pill | Foundayo | |
|---|---|---|---|---|
Active ingredient | Tirzepatide | Semaglutide | Semaglutide (oral) | Orforglipron |
Drug class | Dual GIP/GLP-1 agonist | GLP-1 agonist (peptide) | GLP-1 agonist (peptide) | GLP-1 agonist (non-peptide, small molecule) |
How it's taken | Weekly injection | Weekly injection | Daily tablet | Daily tablet |
Food/timing rules | Any time, with or without food | Any time, with or without food | Strict: empty stomach, ≤4oz water, wait 30 min before food/drink/meds | None; any time, with or without food or water |
Dosing schedule | 2.5→5→7.5→10→12.5→15mg, titrated every 4 weeks | 0.25→0.5→1→1.7→2.4mg (also new 7.2mg HD dose) | 1.5→4→9→25mg | 0.8→2.5→5.5→9→14.5→17.2mg, titrated every 30 days |
Clinical trial | SURMOUNT program, 72 weeks | STEP program, 68 weeks | OASIS trial, ~64 weeks | ATTAIN program, 72 weeks |
Avg. weight loss | 15–22.5% (highest dose) | ~15%, up to 20% with adherence | 14–17% vs. ~2% placebo | 7.4–11.1% vs. 2.1% placebo |
Head-to-head data | In SURPASS-2, reduced HbA1c by up to 2.30% vs. 1.86% for semaglutide | - | - | - |
Common side effects | Nausea, diarrhea, vomiting, constipation, decreased appetite, indigestion | Nausea, diarrhea, vomiting, constipation, headache, fatigue | Same GI profile as injection | Nausea, diarrhea, constipation, vomiting, hair loss |
Alcohol | Worsens nausea/GI symptoms, complicates blood sugar | Same | Same | Same; many patients report alcohol “hits harder” |
Surgery/anesthesia | Inform care team, aspiration risk from delayed gastric emptying | Same | Same | Same, explicitly flagged in FDA label |
Pregnancy | Contraindicated | Contraindicated, pregnancy registry exists | Contraindicated | Contraindicated, pregnancy registry exists |
Biggest practical advantage | Strongest average results (dual mechanism) | Longest real-world track record | Oral, 14x easier to stay on | No fasting rule at all |
Biggest practical drawback | Injection required | Injection required | Strict 30-min fasting window | Lowest average weight-loss % of the four; newest, least long-term data |
Locations
UAE
UK
1 Knightsbridge, Unit A
SW1X 7LX London
1 Knightsbridge, Unit A SW1X 7LX London
Contact Details
Newsletter
Subscribe to receive marketing updates. Opt out anytime. See our Privacy Policy.
Subscribe to receive marketing updates. Opt out anytime. See our Privacy Policy.
GluCare Integrated Diabetes Center L.L.C. (Trading as Metabolic) | Copyright © Metabolic Health. All Rights Reserved. | MOHAP License Number: MAW5UUEI-201025
GluCare Integrated Diabetes Center L.L.C. (Trading as Metabolic) | Copyright © Metabolic Health. All Rights Reserved. | MOHAP License Number: MAW5UUEI-201025
